# Ajanta Pharma (AJANTPHARM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/ajantpharm

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹3,300
- Change: +0.55%
- As of: 2026-11-06
- 1D return: +0.55%
- 5D return: -5.95%
- 1M return: -3.95%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

AJANTPHARM (₹3,289.00) exhibits a near-term technical weakness against a longer-term bullish backdrop. On the daily chart, price action is below key short-term moving averages (20-day and 50-day EMA/SMA) and the Supertrend, which is bearish. Trend strength is weak, with an ADX of 14.49, indicating a lack of directional conviction despite recent volatility anomalies on October 30. The stock is trading in the lower half of its 20-day range (+21.2%) but remains well above its 200-day SMA, preserving the long-term uptrend.

Conversely, the monthly and weekly charts remain constructive. The monthly trend is strong (ADX 42.16) with price above all major averages and the Supertrend. The weekly structure also shows bullish momentum, with price above the 50-period averages and Supertrend. This divergence suggests that while short-term sellers are active, the broader intermediate and long-term trends have not yet been invalidated.

Key levels to monitor include immediate resistance at ₹3,308.37 (pivot) and ₹3,314.50 (high), with support nearby at ₹3,280.43 (low). A break below ₹3,280 could test lower support at ₹3,244.17. Conversely, a sustained move above ₹3,314.50 would be required to confirm a resumption of the daily uptrend. Volatility is elevated, with annualized volatility at +29.7% and current drawdown at -11.5%.

- Daily trend is weak and bearish (price below 20/50 EMA/SMA and Supertrend; ADX 14.49), contrasting with strong monthly (ADX 42.16) and established weekly (ADX 36.15) bullish structures.
- Immediate resistance sits at ₹3,308.37 and ₹3,314.50; immediate support is at ₹3,280.43, with secondary support at ₹3,244.17.
- Price is positioned +21.2% into the 20-day range and +63.7% into the 252-day range, indicating near-term consolidation within a longer-term uptrend.
- Volatility remains high (annualized +29.7%, ATR 3.52%), with current drawdown at -11.5% from available highs.

- Doji
- Morning Star
- Inside Bar

### News Context

In the seven-day window leading up to November 6, 2026, the primary material development for Ajanta Pharma was a broker recommendation update. On November 2, brokerage firm Prabhudas Lilladher issued a 'Buy' rating for the company's shares, setting a price target of ₹4,250. This external analyst opinion provides a specific valuation benchmark and sentiment indicator for retail investors monitoring the stock. As with all third-party ratings, this view reflects the analyst's independent assessment and should not be interpreted as a guaranteed outcome or investment advice from Faxioms.

- {'date': '2026-11-02', 'detail': "Prabhudas Lilladher assigned a 'Buy' rating to Ajanta Pharma.", 'event': 'Brokerage Recommendation'}
- {'metric': 'Price Target', 'source': 'Prabhudas Lilladher', 'value': '₹4,250'}

- [Buy Ajanta Pharma; target of Rs 4250: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/earnings/buy-ajanta-pharma-target-of-rs-4250-prabhudas-lilladher-14066163.html)

### Official Filings

Ajanta Pharma Limited reported unaudited financial results for the quarter and half-year ended September 30, 2026, following a Board meeting on October 30, 2026. The company posted strong growth, with consolidated revenue from operations rising 33% to ₹1,794 crore in Q2 FY2027 (up from ₹1,354 crore) and profit after tax increasing 49% to ₹388 crore (up from ₹260 crore). For the first half of FY2027, consolidated revenue grew 29% to ₹3,420 crore, while profit after tax rose 40% to ₹722 crore. These figures were subject to limited review reports by B S R & Co. LLP, which indicated no material misstatements or disclosure omissions. An earnings call was held on October 30, 2026, with transcripts and recordings subsequently filed with the exchanges.

- Q2 FY2027 consolidated revenue reached ₹1,794 crore, a 33% increase year-on-year from ₹1,354 crore.
- Q2 FY2027 consolidated profit after tax stood at ₹388 crore, up 49% from ₹260 crore in the prior period.
- H1 FY2027 consolidated revenue was ₹3,420 crore (up 29%) and profit after tax was ₹722 crore (up 40%).
- Auditors B S R & Co. LLP issued limited review reports stating nothing came to their attention indicating material misstatement.

- [Ajanta Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/AJANTPHARM_04112026114303_Writtentranscriptofcall04112026.pdf)
- [AJANTA PHARMA LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20261104_114844166.xml)
- [Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/AJANTPHARM_02112026104134_Newspaperpublication30102026.pdf)
- [Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/PRACHI_30102026125942_BMOutcome30102026.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1749772_30102026030631_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1749791_30102026031429_WEB.xml)
- [Ajanta Pharma Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30102026174757_AudioRecordingofEarningCall30102026.pdf)
- [AJANTA PHARMA LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20261030_175152768.xml)
- [NAME OF PROMOTER(S) OR PACS WITH HIM : Aayush Agrawal, trustee Aayush Agrawal Trust](https://nsearchives.nseindia.com/corporate/AJANTPHARM_10212026140918.zip)
- [AJANTA PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1894_WebXMLFile_20261015_103440161.xml)

### Fundamentals

Ajanta Pharmaceuticals demonstrates a robust operating trajectory with accelerating top-line growth and improving profitability in the second quarter of FY2026-27. Revenue from operations rose sequentially to ₹1,794 crore, up from ₹1,626 crore in Q1, while net profit increased to ₹388 crore from ₹334 crore. This momentum is consistent with strong year-on-year trends, where TTM sales reached ₹6,217 crore (up from ₹5,453 crore in Mar 2026) and TTM net profit grew to ₹1,263 crore. Earnings quality remains high, evidenced by a Return on Equity of 27% for the last fiscal year and a Compounded Profit Growth of 30% over the trailing twelve months.

Financial health is supported by solid cash generation, though working capital dynamics require monitoring. Cash from Operating Activity was ₹529 crore in Mar 2026, down from ₹1,157 crore in Mar 2025, coinciding with an increase in the Cash Conversion Cycle to 246 days. The balance sheet shows total assets growing to ₹6,425 crore as of Sep 2026, with investments rising to ₹620 crore. Promoter holding decreased slightly to 63.47% in Sep 2026, while DIIs increased their stake to 21.94%. The company continues to invest in capacity, with Capital Work-in-Progress (CWIP) increasing to ₹327 crore as of Sep 2026.

- Revenue accelerated to ₹1,794 crore in Q2 FY2026-27, up sequentially from ₹1,626 crore in Q1, contributing to TTM sales of ₹6,217 crore.
- Net profit reached ₹388 crore in Q2 FY2026-27, supporting a TTM net profit of ₹1,263 crore and a Last Year ROE of 27%.
- Cash from Operating Activity declined to ₹529 crore in Mar 2026 from ₹1,157 crore in Mar 2025, while the Cash Conversion Cycle extended to 246 days.
- Promoter stake diluted to 63.47% in Sep 2026 as DIIs increased holdings to 21.94%; CWIP rose to ₹327 crore indicating ongoing capex.

### Bear Case

Technical indicators for Ajanta Pharmaceuticals (NSE) present a mixed but cautionary near-term picture as of November 5, 2026. While the monthly trend remains bullish, the daily chart shows bearish momentum with the SuperTrend signaling downside pressure and negative slopes across key moving averages (EMA-20: -18.38; SMA-20: -50.03). The stock has experienced significant volatility, evidenced by an annualized volatility of +29.7% and an Average True Range (ATR) of 3.52%. Price action is currently constrained within a tight range between immediate support at ₹3,280.43 and resistance at ₹3,308.37, reflecting indecision. Short-term performance has been weak, with returns of -0.8% over one day, -5.7% over one month, and -7.9% over twenty days. Although the stock is up +26.0% year-over-year, it is currently trading in a current drawdown of -11.5% from its recent peak, with a historical maximum drawdown of -20.8%, indicating potential vulnerability to further corrections if support levels fail.

- Daily technicals are bearish: SuperTrend direction is down, with negative slopes on EMA-20 (-18.38) and SMA-20 (-50.03), contrasting with a bullish monthly outlook.
- Short-term momentum is weakening: Returns are negative over 1 day (-0.8%), 20 days (-7.9%), and 1 month (-5.7%).
- High volatility and drawdown risk: Annualized volatility stands at +29.7% with ATR at 3.52%; the stock is currently in an -11.5% drawdown, near its historical max of -20.8%.
- Price consolidation: Trading between immediate support (₹3,280.43) and resistance (₹3,308.37) suggests limited upside momentum in the near term.

- [Buy Ajanta Pharma; target of Rs 4250: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/earnings/buy-ajanta-pharma-target-of-rs-4250-prabhudas-lilladher-14066163.html)
- [Ajanta Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/AJANTPHARM_04112026114303_Writtentranscriptofcall04112026.pdf)
- [AJANTA PHARMA LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20261104_114844166.xml)
- [Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/AJANTPHARM_02112026104134_Newspaperpublication30102026.pdf)
- [Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/PRACHI_30102026125942_BMOutcome30102026.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1749772_30102026030631_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1749791_30102026031429_WEB.xml)
- [Ajanta Pharma Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30102026174757_AudioRecordingofEarningCall30102026.pdf)
- [AJANTA PHARMA LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20261030_175152768.xml)
- [NAME OF PROMOTER(S) OR PACS WITH HIM : Aayush Agrawal, trustee Aayush Agrawal Trust](https://nsearchives.nseindia.com/corporate/AJANTPHARM_10212026140918.zip)

### FAQs

**What were Ajanta Pharma's financial results for the second quarter of FY2027?**

For the quarter ended September 30, 2026, Ajanta Pharma reported consolidated revenue from operations of ₹1,794 crore, a 33% increase from ₹1,354 crore in the prior year. Profit after tax rose 49% to ₹388 crore from ₹260 crore. The Board approved these unaudited results on October 30, 2026.

**How has Ajanta Pharma performed over the past year and what is its current valuation context?**

The stock has delivered a +26.0% return over the last one year, with a year-to-date return of +11.9%. As of November 5, 2026, the market capitalization stood at approximately ₹41,445 crore, with the share price closing at ₹3,289.00.

**What are the key technical support and resistance levels for the stock?**

As of November 5, 2026, immediate resistance is observed at ₹3,308.37 (pivot) and ₹3,314.50 (high). Key support levels are located at ₹3,280.43 (low), ₹3,244.17 (low), and ₹3,216.23 (low). The stock experienced a current drawdown of -11.5% from its peak.

**Has any brokerage firm issued a recent recommendation or target price for Ajanta Pharma?**

Prabhudas Lilladher has issued a 'Buy' recommendation for Ajanta Pharma, setting a price target of ₹4,250. This view was reported in news releases dated around November 6, 2026.

- [Buy Ajanta Pharma; target of Rs 4250: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/earnings/buy-ajanta-pharma-target-of-rs-4250-prabhudas-lilladher-14066163.html)
- [Ajanta Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/AJANTPHARM_04112026114303_Writtentranscriptofcall04112026.pdf)
- [AJANTA PHARMA LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20261104_114844166.xml)
- [Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/AJANTPHARM_02112026104134_Newspaperpublication30102026.pdf)
- [Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/PRACHI_30102026125942_BMOutcome30102026.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1749772_30102026030631_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1749791_30102026031429_WEB.xml)
- [Ajanta Pharma Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30102026174757_AudioRecordingofEarningCall30102026.pdf)
- [AJANTA PHARMA LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20261030_175152768.xml)
- [NAME OF PROMOTER(S) OR PACS WITH HIM : Aayush Agrawal, trustee Aayush Agrawal Trust](https://nsearchives.nseindia.com/corporate/AJANTPHARM_10212026140918.zip)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹3,299.5
- Risk regime: Price Risk Currently Contained

### Support levels
- 2932
- 2721.0052734375
- 2657.25

### Resistance levels
- 3314.5
- 3490.1875
- 3614.0687500000004

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.55% |
| return_10 | +0.49% |
| return_1m | -7.65% |
| return_1y | +28.46% |
| return_20 | -3.95% |
| return_3m | -4.91% |
| return_5 | -5.95% |
| return_6m | +6.58% |
| return_since_start | +10.21% |
| return_ytd | +12.31% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -20.81% |
| annualized_volatility | +29.65% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Ajanta Pharma Limited FY2026-27 Q2: Revenue up 33% YoY

Revenue from operations rose 32.5% year on year and 10.3% sequentially to ₹1,794 crore in the quarter ended 30 September 2026. Profit before tax increased 57.0% year on year to ₹535 crore, while profit for the period rose 49.2% to ₹388 crore.

## Revenue and expenses

Revenue from operations increased for four consecutive quarters, from ₹1,354 crore in Q2 FY2025-26 to ₹1,794 crore in Q2 FY2026-27. Total income grew 7.9% sequentially to ₹1,832 crore. Expenses rose 3.7% sequentially to ₹1,296 crore, while other expenses declined 3.2% to ₹478 crore.

## Profitability

Profit before tax increased from ₹447 crore in Q1 FY2026-27 to ₹535 crore in Q2, and was up 57.0% from ₹341 crore in Q2 FY2025-26. Profit for the period rose 16.1% sequentially to ₹388 crore, while comprehensive income increased 19.1% to ₹393 crore. Tax expense rose 30.6% sequentially to ₹147 crore. Finance costs declined 29.6% to ₹2.24 crore.

## Balance sheet

At 30 September 2026, total assets were ₹6,425 crore and equity attributable to owners of the parent was ₹4,858 crore. Equity was ₹4,527 crore at 31 March 2026 and ₹4,315 crore at 30 September 2025. Cash and cash equivalents were ₹90 crore, down from ₹103 crore at 31 March 2026.

Inventories stood at ₹967 crore at quarter-end. Trade receivables were ₹1,864 crore, broadly unchanged from ₹1,854 crore at 31 March 2026 but up from ₹1,448 crore at 30 September 2025. Trade payables were ₹571 crore, compared with ₹544 crore at 31 March 2026.

## Key Takeaway

Revenue and profit grew strongly year on year, with profit before tax rising faster than revenue. Receivables remained near their March level, while cash was lower; both are relevant alongside the quarter’s earnings growth.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +63.48%
- FII holding: +7.68%
- DII holding: +21.80%
- Mutual fund holding: +18.10%
- Retail holding: +5.71%
- Promoter pledged: +0.00%

### Major reported shareholders

- Rajesh M Agrawal, trustee Rajesh Agrawal Trust — +14.47%
- Yogesh M Agrawal, trustee Yogesh Agrawal Trust — +14.47%
- Aayush M Agrawal, trustee Aayush Agrawal Trust — +11.30%
- Ravi P Agrawal, trustee Ravi Agrawal Trust — +10.24%
- Gabs Investments Pvt Ltd — +10.08% (Bodies Corporate)
- Kotak Flexicap Fund — +3.28%
- Uti-Flexi Cap Fund — +3.11%
- Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund — +2.78%
- Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal — +2.68%
- Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Midcap Fund — +2.21%

## Official filings

- 2026-11-04 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_04112026114303_Writtentranscriptofcall04112026.pdf)
- 2026-11-04 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20261104_114844166.xml)
- 2026-11-02 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_02112026104134_Newspaperpublication30102026.pdf)
- 2026-10-30 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PRACHI_30102026125942_BMOutcome30102026.pdf)
- 2026-10-30 — Financial Results Filing: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1749772_30102026030631_WEB.xml)
- 2026-10-30 — Financial Results Filing: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1749791_30102026031429_WEB.xml)
- 2026-10-30 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30102026174757_AudioRecordingofEarningCall30102026.pdf)
- 2026-10-30 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20261030_175152768.xml)
- 2026-10-21 — Regulatory Filing: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_10212026140918.zip)
- 2026-10-15 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1894_WebXMLFile_20261015_103440161.xml)
- 2026-10-15 — Board Meeting Notice: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1894_WebXMLFile_20261015_103440161.xml)
- 2026-10-15 — Board Meeting Notice: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_15102026103125_BMIntimation15102026.pdf)
- 2026-10-15 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_15102026162121_Investorcallintimation15102026.pdf)
- 2026-10-15 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20261015_162645554.xml)
- 2026-10-13 — Shareholding Disclosure: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1736523_13102026103758_WEB.xml)
- 2026-10-08 — Regulatory Filing: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAST_10082026115634_53869.zip)
- 2026-10-08 — Regulatory Filing: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAST1_10082026124616.zip)
- 2026-10-07 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_07102026135556_74_5_30092026.pdf)
- 2026-09-30 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_30092026092944_SR2026.pdf)
- 2026-09-25 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_25092026094828_TWClosure30092026.pdf)
- 2026-09-25 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_1894_WebXMLFile_20260925_095032297.xml)
- 2026-09-22 — Regulatory Filing: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_09222026142511.zip)
- 2026-08-31 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_31082026101535_Newspaperadv31082026.pdf)
- 2026-08-31 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AJANTPHARM_31082026114634_Investorparticipation31082026.pdf)
- 2026-08-31 — Generic Announcement: Ajanta Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1894_WebXMLFile_20260831_114909008.xml)

## News and market events

- 2026-11-02 — MONEYCONTROL: **Buy Ajanta Pharma; target of Rs 4250: Prabhudas Lilladher** — Brokerage firm Prabhudas Lilladher has issued a 'Buy' recommendation for Ajanta Pharma with a price target of Rs 4,250. — [Source](https://www.moneycontrol.com/news/business/earnings/buy-ajanta-pharma-target-of-rs-4250-prabhudas-lilladher-14066163.html)
- 2026-10-30 — The Hindu: **Q2 Results 30th Oct Highlights: GAIL, IOC, Sun Pharma, Aditya Birla, BOB, Aether, Smartworks Q2 PAT rise, Zee Entertainment con. PAT declines, Dixon's profit fall, Reliance, Jio Platforms, BEL, GE Vernova, Lodha, Delhivery, NTPC Green to announce Q2 results** — Market participants reacted to the day's Q2 results with specific stocks identified as gainers and losers. Trent, IndiGo, Deepak Nitrite, and Milky Mist were among the gainers, while Coal India, Strides Pharma, Blue Star, CAMS, Equitas SFB, and Godrej Consumer were among the losers. — [Source](https://www.thehindubusinessline.com/markets/q2-results-today-highlights-reliance-ind-jio-platforms-sun-pharma-dixon-bel-ioc-bob-gail-ge-vernova-lodha-developers-max-healthcare-ntpc-delhivery-aether-company-results-30-october-2026/article71640116.ece)
- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-08-18 — Mint: **Stock market today: Gift Nifty hints a weak start; eight day trading stocks to buy on Tuesday, 18 August** — Sensex and Nifty 50 are set to open lower due to mixed global cues. Brent crude prices have risen amid US-Iran conflict tensions, raising concerns over energy supplies. Analysts suggest cautious trading with key levels for Nifty 50 and Bank Nifty indicating potential selling pressure. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-gift-nifty-hints-a-weak-start-eight-day-trading-stocks-to-buy-on-tuesday-18-august-11787019135761.html)
- 2026-08-13 — Economic Times: **Ahead of Market: 10 things that will decide stock market action on Friday** — Sensex gained 114 points while Nifty fell over 40 points on expiry day, reflecting divergent benchmark moves. Softer inflation supported sentiment, but elevated crude prices and geopolitical risks kept investors cautious, with Nifty remaining rangebound between key technical levels. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/ahead-of-market-10-things-that-will-decide-stock-market-action-on-friday/articleshow/133218209.cms)
- 2026-07-30 — CNBC-TV18: **Q1 Results LIVE Updates: Hyundai Motor India profit falls 35%, Mankind Pharma margin rises** — Q1 Results LIVE Updates: Bajaj Finance, M&M and Tata Steel are the three Nifty results for the day, along with broader market names like Hyundai Motor, Vedanta, Vedanta Aluminium, Swiggy, Mazagon Dock, Torrent Pharma, Thermax and many others. Eicher Motors, Dabur, three Vedanta demerged units, Bajaj Housing, Hexaware and many more also react to numbers. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-bajaj-finance-mm-tata-steel-eicher-dabur-mazagon-dock-swiggy-syngene-irfc-vedanta-aluminium-mtar-hyundai-lic-liveblog-19957385.htm)
- 2026-07-30 — CNBC-TV18: **Market close | Stock Market Highlights: Late buying lifts Sensex 273 pts, Nifty settles above 24,300; auto stocks shine** — Sensex Today | Stock Market LIVE Updates: Today is the monthly expiry of the Sensex contracts. 24,000 on the downside is key for the Nifty, while the July 17 high of 24,367 is the first hurdle to cross on the upside — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-expiry-infosys-it-eicher-dabur-vedanta-irfc-asian-paints-share-price-liveblog-19957305.htm)
- 2026-07-30 — The Hindu: **Q1 Results Today Live: Vedanta Aluminium Q1 profit zooms, M&M, Gillette, Ajanta Pharma, IRFC, ICRA profit rise, Westlife profit falls, Bajaj Finance, Tata Steel, Vedanta, Torrent Pharma, Hyundai Motor, Swiggy, NSDL to announce Q1 results** — Q1 Results Today, 30th July 2026 Live Updates: Stay tuned for more from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-bajaj-finance-mampm-tata-steel-swiggy-awl-agri-torrent-pharma-hyundai-motor-irfc-mankind-vedanta-gillette-mazagon-thermax-ajanta-nuvama-nsdl-niva-bupa-results-30-july-202/article71280963.ece)
- 2026-07-30 — The Hindu: **Sensex today | Stock Market Live: Sensex, Nifty trade flat; IT stocks outperform in cautious market** — Sensex, Nifty, Stock Price Live Updates: Indian benchmark indices traded in a narrow range on Thursday, with gains in IT stocks led by Persistent Systems, Wipro and Coforge helping offset global uncertainty over the Fed, elevated crude oil prices and geopolitical tensions in West Asia, while investors remained focused on Q1 earnings. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-30th-july-2026/article71281731.ece)
- 2026-07-24 — Mint: **Trump's tariff policy: Abbott India, Ajanta Pharma to Alembic — pharma stocks crash up to 4%** — Pharma stocks dipped on July 24 after President Trump announced a phased tariff plan for imported generic medicines, raising concerns for Indian exporters. Abbott India led losses at 3.69%, prompting fears over the future of American production and long-term impacts on stocks. — [Source](https://www.livemint.com/market/stock-market-news/trumps-tariff-policy-abbott-india-ajanta-pharma-to-alembic-pharma-stocks-crash-up-to-4-11784869745089.html)
- 2026-07-23 — Economic Times: **Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investors** — Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India's vital role in supplying affordable medicines to the US. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pharma-stocks-slide-as-trumps-100-generic-drug-tariff-plan-spooks-investors/articleshow/132570049.cms)
- 2026-07-22 — The Hindu: **Sensex today | Stock Market Live: Sensex down 500 pts, Nifty slips to 24,000; Nifty Pharma index in red on Trump's tariffs** — Sensex, Nifty, Share Prices LIVE: Sensex fell 381.02 pts or 0.49% to 77,089.09 at 9.17 am after opening at 77,384.95 from the previous close of 77,470.11; Nifty 50 depreciated 106.75 pts or 0.44% to 24,080.95 — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-22nd-july-2026/article71249266.ece)

## Business profile

**Strategic vision:** Develops, manufactures, and markets pharmaceutical formulations.

### Business segments
- **Branded Generics (India):** Focuses on specialty therapeutic segments in India with a direct marketing presence. Primary areas include Cardiology, Dermatology, Ophthalmology, and Pain Management.
- **Branded Generics (Emerging Markets):** Serves countries in Asia, Africa, and the Middle East with a localized product portfolio tailored to local healthcare demands.
- **Generics (USA):** Focuses on niche and complex formulations in the United States, utilizing a selective commercial strategy.
- **Institutional Segment:** Provides anti-malarial products and other essential medicines to institutional buyers and health programs, primarily in Africa.

### Competitive strengths
- Dedicated R&D center developing formulations, APIs, and analytical methodologies.
- Manufacturing facilities producing finished dosages and APIs under global health authority regulations.
- Ability to develop multiple dosage forms including tablets, capsules, injectables, nasal sprays, and topical creams.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%
- [Gland Pharma Limited (Healthcare)](https://faxioms.com/stocks/gland) — +0.78%
- [Glenmark Pharmaceuticals Limited (Healthcare)](https://faxioms.com/stocks/glenmark) — +4.36%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/ajantpharm
Markdown representation: https://faxioms.com/stocks/ajantpharm?render=md